At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Randomized Study Evaluating a Switch From a Regimen of Two Nucleoside Reverse Transcriptase Inhibitors Regimen Plus Any Third Agent to Either a Regimen of Atazanavir/Ritonavir Once Daily and Raltegravir Twice Daily or to a Regimen of Atazanavir/Ritonavir Once Daily and Tenofovir/Emtricitabine Once Daily in Virologically Suppressed HIV-1 Infected Subjects With Safety and/or Tolerability Issues on Their Present Treatment Regimen.
In Brief
A Phase 4 clinical trial evaluating Atazanavir, Ritonavir (heat-stable), and 2 other interventions for HIV, Combination Therapy. Completed, enrolled 132 participants across 38 sites in 7 countries.
Detailed Summary
The purpose of this study is to determine whether HIV-1-infected patients, who are virologically suppressed on a regimen of 2 nucleoside reverse transcriptase inhibitors plus any third agent but are experiencing safety and/or tolerability issues, will maintain virologic suppression after switching to a regimen of heat-stable ritonavir boosted atazanavir, 300/100 mg, once daily plus raltegravir, 400 mg, twice daily.
Study Details
Timeline
Interventions
Capsules, Oral, 300mg, Once daily, 48 weeks
Tablets, Oral, 100 mg, Once daily, 48 weeks
Tablets, Oral, 400 mg, Twice daily, 48 weeks
Tablets, Oral, 300/200 mg, Once daily, 48 weeks